The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.
In a unanimous move, Portland will make personal, non-commercial use and sharing of natural psychedelics a low police priority—without legalizing sales or impaired driving.
A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.
Psychedelic Alpha spotlights Kimon de Greef’s look at 5‑MeO‑DMT’s ascent from Sonora to pharmaceutical interest. Here’s what DMV readers should watch and why it matters.
Psychedelic Alpha reports that two psychiatrists in New Zealand have been cleared to prescribe MDMA for PTSD. Here’s what happened and what DMV readers should know.
As a historic federal cannabis rescheduling hearing unfolds, ATACH’s Michael Bronstein readies for the next round. Here’s what’s known—and what DMV readers should watch.
MDMA PTSD refiling, a first LSD Phase 3 readout, HRSA’s 59 RFI responses on psychedelic care access, J&J’s neuroplastogen bet, and an FDA pick to watch.
Wan't to get Cannabis News and Blog Updates from Bud Lords Weed Delivery in Washington DC? Sign up and Become a member to get updates on new blogs and washington dc weed events.